Phase II study of bemnifosbuvir in high-risk participants in a hospital setting with moderate COVID-19

por Horga, Arantxa, Kuritzkes, Daniel R., Kowalczyk, John J., Pietropaolo, Keith, Belanger, Bruce, Lin, Kai, Perkins, Kristen, Hammond, Janet
Publicado 2023

A Phase 2 Randomized Trial Evaluating the Antiviral Activity and Safety of the Direct-Acting Antiviral Bemnifosbuvir in Ambulatory Patients with Mild or Moderate COVID-19 (MOONSONG...

por Boffito, Marta, Dolan, Eamon, Singh, Karishma, Holmes, William, Wildum, Steffen, Horga, Arantxa, Pietropaolo, Keith, Zhou, Xiao-Jian, Clinch, Barry, Collinson, Neil, Ukachukwu, Vincent
Publicado 2023

Oral bemnifosbuvir (AT-527) vs placebo in patients with mild-to-moderate COVID-19 in an outpatient setting (MORNINGSKY)

por Horga, Arantxa, Saenz, Rebecca, Yilmaz, Gürdal, Simón-Campos, Abraham, Pietropaolo, Keith, Stubbings, William J, Collinson, Neil, Ishak, Laura, Zrinscak, Barbara, Belanger, Bruce, Granier, Catherine, Lin, Kai, C Hurt, Aeron, Zhou, Xiao-Jian, Wildum, Steffen, Hammond, Janet
Publicado 2023